Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28545841 | 0.83 | — | — | |
| SCHEMBL15333490 | 0.79 | — | — | |
| SCHEMBL14048307 | 0.77 | — | — | |
| SCHEMBL20996792 | 0.77 | — | — | |
| SCHEMBL14022084 | 0.77 | FDPS (0.34) | — | |
| SCHEMBL15266380 | 0.77 | TP53 (0.34) | TP53TSHR | |
| SCHEMBL5364973 | 0.76 | TP53 (0.35) | TP53TSHR | |
| SCHEMBL270156 | 0.74 | — | — | |
| SCHEMBL26625981 | 0.73 | TP53 (0.41) | TP53TSHR | |
| SCHEMBL14034844 | 0.73 | TP53 (0.37) | TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120263789-A1 | DELAYED RELEASE RASAGILINE FORMULATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2012-10-18 | — | — | US | disclosed |
| US-20120100189-A1 | DELAYED RELEASE RASAGILINE MALATE FORMULATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2012-04-26 | — | — | US | disclosed |
| US-20120003310-A1 | DELAYED RELEASE RASAGILINE FORMULATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-01-05 | — | — | US | disclosed |
| US-20100189791-A1 | Delayed release rasagiline malate formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20100189788-A1 | Delayed release rasagiline base formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | disclosed |
| US-20090181086-A1 | Rasagiline formulations, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100189-A1 | DELAYED RELEASE RASAGILINE MALATE FORMULATION | MDH1, MDH2, SLC25A11 | TP53 3603/4885TSHR 4315/4885 |
| US-20120003310-A1 | DELAYED RELEASE RASAGILINE FORMULATION | RAB7A, RAB5B, RAB27A | TP53 3320/4885TSHR 2264/4885 |
| US-20100189788-A1 | Delayed release rasagiline base formulation | RAB7A, RAB27A, RAB5B | TP53 4460/4885TSHR 2402/4885 |
| US-20090181086-A1 | Rasagiline formulations, their preparation and use | RAB5B, RAB27A, RAB29 | TP53 4093/4885TSHR 3463/4885 |
| US-20100189791-A1 | Delayed release rasagiline malate formulation | MDH1, MDH2, SLC25A11 | TP53 3603/4885TSHR 4315/4885 |
| US-20120263789-A1 | DELAYED RELEASE RASAGILINE FORMULATION | RAB7A, RAB27A, RAB35 | TP53 4277/4885TSHR 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.